Health

Compass Pathways CEO: Psychedelics company will ‘go slow before we go fast’

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 15/10/2026, 00:06:24 UTC.

Briefings

Compass Pathways CEO Kabir Nath announced a cautious rollout strategy for psychedelics therapy, stating the company will 'go slow before we go fast' to mitigate early negative experiences. This decision comes as the company prepares to submit its therapy for FDA regulatory review in the coming quarter, marking a potential shift in the mental health sector toward a more measured launch approach.

Key points

• Compass Pathways CEO Kabir Nath warned that early negative experiences from patients or providers could damage the broader psychedelic therapy sector.
• The company is preparing to complete the submission of its psychedelic therapy for regulatory review this quarter.

Context and limitations

The article provides no specific dates for the FDA submission, no quantitative data on patient outcomes, and no details on the timeline for the first potential approval.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 15/10/2026, 00:15:19 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeicjwxybmb5afpoxizc6yjoa5ibkc6mi4tnvpiqszt5mjni6xzz2ge